Egle Therapeutics Raises € 40 Million in Series A to Develop First-Class T-Regulatory Cell Therapies Based on Treg’s Hungry People | DNA RNA and cells


Egle Therapeutics Raises € 40 Million in Series A to Develop First-Class T-Regulatory Cell Therapies Based on Treg Hungers

LSP and Bpifrance, through its InnoBio 2 fund, co-lead the international syndicate of investors

PARIS, France I October 22, 2021 I Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on the development of first-class immunotherapies targeting immunosuppressive regulatory T cells (Tregs) for oncology and autoimmune diseases, today announces that it has completed a series of 40 million euros ($ 46.4 million) funding. Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund. Fund +, Bioqube Ventures and Takeda Ventures, Inc. also participated in this round.

Egle Therapeutics was founded in early 2020 with the vision to be a game-changer in the field of Treg immunomodulation through the unique concept of starving Tregs and specifically targeting the most immunosuppressive. Stemming from Institut Curie, Egle’s scientific foundation draws on unprecedented, calculus-based variants modified by IL-2 and novel tumor-associated Treg targets to create a rich pipeline of immunocytokines first class against the Tregs. The new capital will mainly be used to advance the assets of 2 tracks in the clinic and further strengthen its internal drug pipeline.

“Close a substantial € 40 million Series A with a high-quality syndicate of renowned investors, as well as a partnership with a large large pharma like the one we announced with Takeda in June 2020, all in less month, puts Egle on a trajectory to execute his vision of attacking regulatory T cells to restore immunity in patients with cancer and autoimmune diseases, ”commented Luc Boblet, co-founder and CEO d’Egle. “The funding will give us the appropriate resources to push Treg’s first hungry people into the clinic and we feel very privileged to take on such a responsibility for the benefit of the entire patient community.”

The investor union will join the Egle Therapeutic Council which will be made up of Felice Verduyn-van Weegen (LSP), Vincent Brichard (LSP), Jean-Fran̤ois Morin (Bpifrance РInnoBio 2) and Sacha Mann (Takeda Ventures). Philippe Monteyne (Fund +), Jacques Mizrahi (Bioqube Ventures) and Elisa El Nouchi (Bpifrance InnoBio 2) will join as observers.

“Egle represents a strategic investment in a First-In-Class technological platform based on innovative research with new T regulatory modulations and potential in the fields of oncology and autoimmunity”, commented Vincent Brichard, Venture Partner at LSP. “We feel privileged to be part of such an exciting company with world-class science and we look forward to developing it with the team,” adds Felice Verduyn-van Weegen, partner at LSP.

“InnoBio 2 strives to invest in breakthrough ideas and promote First-In-Class drug candidates. We are delighted to have co-led a funding round that will allow Egle Therapeutics to invest heavily in its platform, technologies, development programs, human resources and, ultimately, to deliver a new generation of immunotherapies. pioneers for patients in need, ”said Jean-François Morin. , investment director at Bpifrance.

About Egle Therapeutics

Created in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial entrepreneur in biotechnology and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM research director, Head of translational immunotherapy team – TransImm – at Institut Curie), Egle Therapeutics is developing First-In-Class immunotherapies targeting immunosuppressive regulatory T lymphocytes (Tregs) for oncology and autoimmune diseases. Key to Egle’s core approach is to leverage its translation-based target discovery platform to unveil novel therapeutic targets Treg and computer-engineered immunocytokines acting as antagonists or as Treg- selective agonists.

About LSP

LSP is one of the largest European investment firms providing finance to life science and healthcare companies. LSP’s management has raised more than 2.7 billion euros ($ 3.2 billion) and has supported the growth of 300 companies since it began investing in 1988, including signing deals such as ‘Argenx, Crucell and Neuravi. With offices in Amsterdam, Munich and Boston, LSP currently has the opportunity to invest through five strategies, each with a distinct investment scope and a dedicated team: LSP 6 invests in private drug and technology development companies early or late stage medical conditions; LSP HEF 2 focuses on private late stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Target audience public health companies; and EBAC is the first healthcare SPAC to focus exclusively on European biotechnology. LSP actively contributes to the global life science industry and the European life science ecosystem by taking on for-profit and non-profit roles as initiators, founders and board members of various private and public bodies and organizations, for example by being the founder and member of the board of directors of the Oncode Institute.

About Bpifrance – InnoBio 2

Bpifrance is the French national investment bank: it finances companies – at all stages of their development – through loans, guarantees, equity investments and export insurance. Bpifrance also offers additional financial services (training, advice) to help entrepreneurs meet their challenges (innovation, export).

InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS and Pasteur Mutualité. InnoBio 2 aims to invest in companies developing innovative products and services, close to or at the start of clinical development, with the objective of bringing them to clinical proof of concept. InnoBio 2 takes minority stakes in companies and can lead or co-lead investment tours.

About Takeda Ventures Inc.

Takeda Ventures, Inc. (TVI) is the corporate venture capital group of Takeda Pharmaceutical Company Limited and was founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through founded partnerships. on venture capital. Their mission is to create strategic growth opportunities for Takeda by creating, managing and investing in companies based on innovation. TVI partners with academic innovators, entrepreneurs and venture capitalists to create and maintain a portfolio of companies in a range of therapeutic areas including oncology, gastroenterology, neuroscience and rare diseases . For more information, visit

About Fund +

Fund + is an open fund for long-term equity investment in innovative life science companies with a focus on Belgium and other European biotech hubs. We want to create sustainable shareholder value, contribute to the development of a leading position in the Life Sciences sector and generate a tangible and beneficial societal impact. Fund + currently has 16 innovative portfolio companies active in different therapeutic areas.

About Bioqube Ventures

Bioqube Ventures is an investment firm specializing in life sciences founded in 2016. The team is made up of investment professionals, industry experts and serial entrepreneurs who have a proven track record in creating and the management of companies on the way to growth. In 2020, Bioqube Ventures launched the Bioqube Factory Fund I with a clear focus on the discovery and development of new therapeutic platforms and assets. With a diversified investment strategy, comprising a business start-up model and industry advice through selected strategic partnerships, Bioqube Ventures will invest exclusively in Europe’s most promising innovative science. Bioqube Factory Fund I is supported by InnovFin Equity, with the financial support of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) set up under the plan to investment for Europe. The aim of the EFSI is to help support the financing and implementation of productive investments in the European Union and to ensure increased access to finance.

About Institut Curie

The Institut Curie, the leading cancer center in France, combines an internationally renowned research center with a leading hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie employs more than 3,700 researchers, doctors and health professionals spread over three sites (Paris, Saint-Cloud and Orsay) in the service of its three missions: care, research and teaching. A private foundation with public utility status, the Institut Curie is authorized to receive donations and bequests, and thanks to the support of its donors, it can make discoveries more quickly, improving treatment and the quality of life of patients.

THE SOURCE: Therapeutic Rule


About Author

Leave A Reply